Clinical Trials Logo

Retinal Degeneration clinical trials

View clinical trials related to Retinal Degeneration.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06167642 Enrolling by invitation - Multiple Sclerosis Clinical Trials

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Start date: May 22, 2023
Phase:
Study type: Observational

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

NCT ID: NCT06162585 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

REMAIN
Start date: December 8, 2023
Phase:
Study type: Observational

This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study

NCT ID: NCT05921162 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

EXTEND
Start date: July 14, 2023
Phase:
Study type: Observational

This study "A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection" is an observational study and will be conducted following Good Clinical Practice (GCP)- International Conference on Harmonization (ICH) guidelines. Eligible subjects satisfying all inclusion and none of the exclusion criteria will be enrolled. All subject who completed the parent clinical study (NSCT/CT/18/01) will undergo safety and efficacy assessments up to 5 years post study drug injection

NCT ID: NCT03772938 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Stem Cells Therapy in Degenerative Diseases of the Retina

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.

NCT ID: NCT03760055 Enrolling by invitation - Glaucoma Clinical Trials

Assessment of Visual Function With a Portable Brain-computer Interface

Start date: February 11, 2019
Phase:
Study type: Observational

1. The purpose of this study is to evaluate the nGoggle's accuracy and repeatability in detecting visual function loss. In addition, the ability to stage glaucomatous damage and investigate the relationship between nGoggle metrics and neural damage in glaucoma will also be evaluated. 2. Longitudinal study, including 200 patients with: glaucoma, suspected of having glaucoma, nonglaucomatous optic neuropathies, AMD, retinal degenerations, other diseases involving the visual pathways, besides healthy controls. Subjects will perform standard ophthalmological exams, and the following research tests: electroencephalogram, visual evoked potentials, and questionnaires. 3. Statistical analyses will be performed by the PI using the software Stata, MATLAB, and MPLUS. Risks are low, consisting of some discomfort, fatigue, dizziness or motion sickness.

NCT ID: NCT02144103 Enrolling by invitation - Clinical trials for Retinal Degeneration

Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration

Start date: May 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall. ADRC will be administered one-time into subtenon space of patient's eyeball. This is a single arm study with no control. All patients receive cell therapy.